Affimed Receives Fast Track Designation for Combination Ther

Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer

29.05.2024 - Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/metastatic cancers in the ongoing AFM24-102 phase 1/2a ... Seite 1

Related Keywords

Mannheim , Baden Wüberg , Germany , Wolfgang Fischer , American Society Of Clinical Oncology On , Fast Track , American Society , Clinical Oncology , Chief Operating Officer ,

© 2025 Vimarsana